MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes

Annals of the Rheumatic Diseases

Volumn 70, Issue 12, 2011, Pages 2075-2081

  Wittkowski, Helmut ^a   Kuemmerle Deschner, Jasmin B ^b   Austermann, Judith ^c   Holzinger, Dirk ^c   Goldbach Mansky, Raphaela ^d   Gramlich, Katharina ^b   Lohse, Peter ^e   Jung, Thomas ^f   Roth, Johannes ^c   Benseler, Susanne M ^g   Foell, Dirk ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CANAKINUMAB; INTERLEUKIN 1; MRP8 PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CINCA SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DRUG DOSE ESCALATION; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MINIMAL RESIDUAL DISEASE; MUCKLE WELLS SYNDROME; PHAGOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALGRANULIN B; CHILD; CHILD, PRESCHOOL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DRUG MONITORING; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-1BETA; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82755197740     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.152496     Document Type: Article

References (33)

1. K anneganti TD, Ozören N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006;440:233-6.
2. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006;440:228-32. (Pubitemid 43372102)
3. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41. (Pubitemid 43372104)
4. Sutterwala FS, Ogura Y, Szczepanik M, et al. Critical role for NALP3/CIAS1/ Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006;24:317-27.
5. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25. (Pubitemid 38388233)
6. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8. (Pubitemid 35453546)
7. Janssen R, Verhard E, Lankester A, et al. Enhanced interleukin-1beta and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2004;50:3329-33. (Pubitemid 39372011)
8. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92. (Pubitemid 44200651)
9. Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12. (Pubitemid 38198844)
10. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-4.
11. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85. (Pubitemid 39488063)
12. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24. (Pubitemid 34214243)
13. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008;58:2432-42.
14. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
15. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009;206:1029-36.
16. Frosch M, Ahlmann M, Vogl T, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60:883-91.
17. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007;3:382-90. (Pubitemid 47034539)
18. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42. (Pubitemid 40516158)
19. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13:1042-9. (Pubitemid 47517513)
20. Loser K, Vogl T, Voskort M, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010;16:713-17.
21. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-73.
22. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011;63:840-9.
23. Foell D, Hernández-Rodríguez J, Sánchez M, et al. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J Pathol 2004;204:311-16. (Pubitemid 39430091)
24. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71. (Pubitemid 46883770)
25. van Zoelen MA, Vogl T, Foell D, et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am J Respir Crit Care Med 2009;180:1098-106.
26. Wittkowski H, Hirono K, Ichida F, et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 2007;56:4174-81. (Pubitemid 350262345)
27. Schulze zur Wiesch A, Foell D, Frosch M, et al. Myeloid related proteins MRP8/ MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:368-73.
28. Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;272:9496-502. (Pubitemid 27154966)
29. Odink K, Cerletti N, Brüggen J, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987;330:80-2. (Pubitemid 17152420)
30. Ehrchen JM, Sunderkötter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009;86:557-66.
31. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007;81:1-5. (Pubitemid 46028489)
32. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998;160:1427-35. (Pubitemid 28093444)
33. Viemann D, Barczyk K, Vogl T, et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood 2007;109:2453-60. (Pubitemid 46425888)